Twenty five years ago, the therapeutic strategy of controlling cancer by broadly targeting collagenase (matrix metalloproteinase (MMP)1), stromelysin-1 (MMP3), and gelatinase A (MMP2), the three then known MMPs, was founded on reducing degradation of basement membrane and extracellular matrix proteins by cancer cells in metastasis and angiogenesis (Liotta et al, 1980; Hodgson, 1995). The gene discussed is MMP3; the disease is cancer.